Dai ichi Life Insurance Company Ltd Has $27.22 Million Holdings in Gilead Sciences, Inc. $GILD

Dai ichi Life Insurance Company Ltd trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.6% during the first quarter, Holdings Channel.com reports. The fund owned 195,288 shares of the biopharmaceutical company’s stock after selling 13,858 shares during the quarter. Gilead Sciences accounts for about 0.8% of Dai ichi Life Insurance Company Ltd’s holdings, making the stock its 22nd biggest position. Dai ichi Life Insurance Company Ltd’s holdings in Gilead Sciences were worth $27,217,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Aviva PLC boosted its stake in Gilead Sciences by 5.4% in the fourth quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock valued at $141,978,000 after buying an additional 59,782 shares in the last quarter. Life Cycle Investment Partners Ltd acquired a new position in Gilead Sciences during the fourth quarter worth about $1,418,000. Beacon Investment Advisory Services Inc. lifted its holdings in shares of Gilead Sciences by 10.3% in the fourth quarter. Beacon Investment Advisory Services Inc. now owns 111,531 shares of the biopharmaceutical company’s stock worth $13,689,000 after acquiring an additional 10,449 shares during the last quarter. NBC Securities Inc. lifted its holdings in shares of Gilead Sciences by 150.3% in the fourth quarter. NBC Securities Inc. now owns 17,147 shares of the biopharmaceutical company’s stock worth $2,105,000 after acquiring an additional 10,296 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its stake in shares of Gilead Sciences by 45.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 243,532 shares of the biopharmaceutical company’s stock valued at $29,891,000 after purchasing an additional 76,432 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the completion of the sale, the insider owned 124,234 shares of the company’s stock, valued at approximately $15,395,077.28. This represents a 2.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the sale, the chief executive officer owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. This trade represents a 2.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 77,000 shares of company stock worth $9,978,740 over the last ninety days. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on GILD shares. Royal Bank Of Canada decreased their price target on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Rothschild & Co Redburn cut their target price on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 target price on shares of Gilead Sciences in a research note on Monday, July 6th. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Finally, Morgan Stanley dropped their price target on Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating for the company in a research note on Wednesday, July 8th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $158.33.

Gilead Sciences Stock Down 1.2%

Shares of NASDAQ GILD opened at $129.31 on Friday. The company has a 50 day simple moving average of $129.55 and a 200 day simple moving average of $135.50. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The firm has a market cap of $160.55 billion, a PE ratio of 17.62 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same period in the previous year, the firm posted $1.81 EPS. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post -0.77 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s payout ratio is 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.